Bristol Myers reinforces neuroscience deals; Iovance prices $150M public offering
Bristol Myers Squibb, a big pharma hardly synonymous with neuroscience drugs, is beefing up its work with two European biotechs in Alzheimer’s and undisclosed neurodegenerative conditions.
The drugmaker is paying $55 million in exchange for the exclusive global license to Prothena’s clinical-stage anti-tau antibody PRX005. Bristol Myers bought the US rights to the potential Alzheimer’s drug for $80 million 25 months ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.